An Introduction to Leukaemia
Treating leukaemia holds numerous challenges, including the need for less toxic and more cost-effective treatments. Important additions to the landscape include targeted treatments such as FLT3 inhibitors, BCL-2 inhibitors and immune therapies such as monoclonal antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapies have been important additions to improve patient outcomes.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
High-Risk* Acute Myeloid Leukaemia in 2022: What is the Go-To Strategy?
Promotional content from Jazz Pharmaceuticals Watch leading experts present and discuss clinical and real-world evidence on the use of Vyxeos Liposomal (daunorubicin 44 mg / cytarabine 100 mg ) for the treatment of high-risk* acute myeloid leukaemia
Treatment in high-risk* acute myeloid leukemia (AML): translating clinical trial efficacy into real-world effectiveness
Promotional content from Jazz Pharmaceuticals. Watch four key videos highlighting the long-term clinical trial data and real-world evidence
Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
Robin Foà: Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]
Elias Jabbour, ASH 2021: Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (PACE and OPTIC Trials)
We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials. Questions 1. What […]
Treating high-risk* acute myeloid leukemia in the real world
Promotional content from Jazz Pharmaceuticals. Watch leading experts present and discuss...
The role of measurable residual disease in acute lymphoblastic leukaemia
Watch leading experts Aaron Logan, Joseph Khoury and Nicola Gökbuget discuss the importance of measurable residual disease reporting in acute lymphoblastic leukaemia, as well as best practice techniques, potential limitations, and future directions.
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!